<DOC>
	<DOCNO>NCT00068250</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy methotrexate temozolomide use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Radiation therapy use high-energy x-rays damage cancer cell . Combining methotrexate , temozolomide , rituximab radiation therapy may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose temozolomide give together methotrexate rituximab follow radiation therapy see well work treat patient primary central nervous system lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Monoclonal Antibody , Radiation Therapy Treating Patients With Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temozolomide combination methotrexate rituximab fractionate whole brain radiotherapy patient primary central nervous system lymphoma . - Compare 2-year survival rate patient receive chemotherapy regimen radiotherapy temozolomide radiotherapy patient treat protocol RTOG-9310 . - Compare tumor response rate patient treat chemotherapy regimen radiotherapy patient treat Radiation Therapy Oncology Group ( RTOG ) , RTOG-9310 . - Determine progression-free survival patient treat regimen . - Determine acute long-term neurologic toxicity regimen patient . - Determine quality life patient treat regimen . OUTLINE : This phase I dose-escalation study temozolomide combination methotrexate rituximab radiotherapy , follow phase II study . Phase I - Pre-radiotherapy chemotherapy : Patients receive rituximab IV 3 day prior first course methotrexate . Patients receive methotrexate IV 4 hour week 1 , 3 , 5 , 7 , 9 ( total 5 dos ) . Patients also receive oral temozolomide daily 5 day week 4 8 . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose 0 3 1 6 patient experience dose-limiting toxicity . - Radiotherapy : Patients undergo whole brain radiotherapy daily 5 day week 11 , 12 , 13 . - Post-radiotherapy chemotherapy : Patients receive oral temozolomide daily day 1-5 begin week 14 . Treatment repeat every 28 day 10 course absence unacceptable toxicity . Phase II - Patients receive treatment phase I MTD temozolomide . Treatment continue absence unacceptable toxicity . Quality life assess baseline , week 10 13 , every 2 month post-radiotherapy temozolomide therapy , end therapy , every 3 month 2 year , every 6 month 3 year , annually thereafter . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 52-64 patient ( 18 patient phase I 46 patient phase II ) accrue study within 19 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm primary central nervous system ( CNS ) lymphoma Based positive biopsy , cerebrospinal fluid , vitreous cytology ( association measurable intraparenchymal tumor ) Bcell type Cluster Differentiation antigen ( CD20 ) + disease Cytology must demonstrate lymphoma OR immunohistochemical diagnosis malignant lymphocytes monoclonal lymphocytic population No evidence systemic lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy At least 8 week Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) great 2 time ULN Alkaline phosphatase great 2 time ULN No active hepatitis B Renal Creatinine clearance least 50 mL/min No renal insufficiency Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No history idiopathic sensitivity drug study No active infection No known anaphylaxis Immunoglobulin E ( IgE ) mediate hypersensitivity murine proteins component rituximab PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy brain , head , neck Surgery No prior organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
</DOC>